Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
Intranasal anti-CD3 immunotherapy for neuroinflammatory diseases
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies for neurological and inflammatory diseases. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to modulate T-cell activity through nasal administration. The 48-patient…
Macrophage-targeted therapeutics for oncology, neurological and fibrotic diseases
Macomics is a University of Edinburgh spin-out developing macrophage-targeted medicines across oncology, neurodegenerative, inflammatory and fibrotic diseases. Its ENIGMAC drug discovery platform combines human macrophage and microglia models derived from induced pluripotent stem cells, gene editing and…
Liver-directed RNA medicines to restore function in chronic liver disease
Apterna is a preclinical biotechnology company developing RNA-based medicines to restore function in damaged livers. Its lead programme is a liver-directed therapy, given by injection under the skin every few months, that silences a single gene which limits the liver's ability to recover from injury. Animal studies…
ADC oncology company developing novel spliceosome-modulating payloads
Akari Therapeutics is a clinical-stage biopharma company developing next-generation bi-functional antibody-drug conjugates for cancer treatment. Its proprietary ADC platform centres on PH1, a novel spliceosome-modulating small molecule payload designed to disrupt RNA splicing in tumour cells and activate anti-tumour…
Immunotherapeutics targeting drug-resistant bacterial infections
Centauri Therapeutics is a clinical-stage immunotherapy company developing treatments for life-threatening infectious diseases using its proprietary platform. The technology uses synthetic bifunctional molecules that recruit and redirect naturally occurring anti-glycan antibodies to target pathogens, engaging both…
CAR-T and bispecific antibody therapies for blood cancers
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for haematological malignancies and autoimmune diseases. Its lead asset, HG-CT-1, is a third-generation anti-FLT3 CAR-T cell therapy for relapsed and refractory acute myeloid leukaemia, currently in a Phase 1…
siRNA gene therapies targeting root causes of ALS and frontotemporal dementia
Crucible Therapeutics Limited is a preclinical-stage biotechnology company developing siRNA-based gene therapies for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia caused by the C9orf72 gene mutation. Its therapeutic approach depletes the SRSF1 protein to suppress production of toxic dipeptide repeat…
DNA damage response platform targeting hard-to-treat solid tumours
Artios Pharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target DNA damage response pathways in cancer cells. The company's pipeline includes alnodesertib, an ATR inhibitor advancing toward late-stage development in ATM-deficient solid tumours, and ART6043, a DNA…
Global biopharma with UK R&D centre on the Wirral Peninsula
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company with a long-established UK R&D site at Moreton on the Wirral Peninsula and its UK and Ireland commercial headquarters in Uxbridge. The Moreton facility, expanded in 2025, conducts chemistry, manufacturing and control activities supporting pharmaceutical…
Engineered hybrid interferon therapeutics for viral and immune-mediated disease
ILC Therapeutics is a pre-clinical biotechnology company developing hybrid interferons, an engineered cytokine drug class combining favourable attributes of multiple naturally occurring interferon subtypes. The platform rationally designs novel candidates with reduced toxicity and pleiotropic activity across multiple…
Allogeneic neutrophil cell therapy platform for solid tumours
LIfT BioSciences is a biotechnology company developing a first-in-class allogeneic neutrophil immunotherapy for the treatment of solid tumours. Its platform produces Immuno-Modulatory Alpha Neutrophils (IMANs) from donor haematopoietic or induced pluripotent stem cells using a proprietary enhancement process. IMANs…
AI platform designing vaccines against current and future pathogens
Baseimmune is a biotechnology company developing a deep learning platform for computational vaccine antigen design. The platform integrates genomic, epidemiological, immunological, and evolutionary data to generate novel synthetic antigens drawn from across an entire pathogen genome, enabling the design of vaccines…
Specialty pharmaceuticals for Parkinson's disease and related neurological conditions
Britannia Pharmaceuticals is a UK-based specialty pharmaceutical company developing and marketing treatments for Parkinson's disease and related conditions including psychosis. The company's product range includes apomorphine-based therapies available in multiple delivery formats, alongside clozapine-based treatment…
Clinical-stage rare disease biotech acquiring deprioritised pharma assets
Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases. Founded in 2015, its business model centres on acquiring clinical-stage programmes deprioritised by large pharmaceutical companies and advancing them through further development. Lead programmes include…
Small molecule protein degraders targeting oncology and CNS disease
Kesmalea Therapeutics is a biotechnology company developing oral small molecule therapeutics that modulate protein homeostasis through targeted protein degradation and stabilisation. The company's platform is designed to convert the potency of protein degrader approaches into orally bioavailable, CNS-penetrant small…
Molecular imaging and targeted cancer therapy agents
Edinburgh Molecular Imaging is a biopharmaceutical company developing molecular imaging and targeted therapeutic agents for cancer and other diseases. Its research includes fluorescent peptide probes for image-guided surgery and radiolabelled compounds directed at c-Met, a receptor expressed in several tumour types.…
Precision oncology biotech targeting novel DNA damage response pathways
Nodus Oncology is a preclinical-stage biotechnology company developing small molecule inhibitors against novel DNA damage response targets for molecularly defined cancer patient populations. The company's pipeline is focused on synthetic lethality and collateral vulnerabilities in tumours with specific DNA repair…
AI-driven delivery platform for siRNA therapies beyond the liver
Undecimal Bio is a biotechnology company developing targeted delivery technologies for small interfering RNA (siRNA) therapeutics beyond the liver. Its DELiveri platform combines large-scale combinatorial chemistry, functional cell-based screening and AI to identify synthetic conjugates that transport siRNA into…
Antisense oligonucleotide therapies for TUBB4A-associated leukodystrophies
SynaptixBio is a biotechnology company developing antisense oligonucleotide therapies for severe inherited leukodystrophies. Its lead programme targets TUBB4A-associated hypomyelinating disorders, including hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). The approach uses synthetic…
Small molecule drug discovery focused on fibrosis and oncology
Redx Pharma is a clinical-stage biotech developing novel small molecule therapeutics for fibrotic disease and cancer. Its pipeline is anchored by zelasudil, a selective ROCK2 inhibitor in clinical development for idiopathic pulmonary fibrosis and other fibrotic indications, and zamaporvint, a Porcupine inhibitor…